[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345854-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345854-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mmp1-and-prss23-induce-par2-biased-agonism-in-painful-oral-cancers","MMP1 and PRSS23 induce PAR2 biased agonism in painful oral cancers","","Protease-activated receptor 2 (PAR2) is a key mediator of oral cancer pain, and patients with metastatic (N+) disease experience greater pain than those with nonmetastatic (N0) cancers. This study shows that proteases overexpressed in N+ painful tumors—matrix metallopeptidase 1 (MMP1) and serine protease 23 (PRSS23)—cause protease-specific PAR2 redistribution and signaling distinct from proteases encoded by genes not differentially expressed. In modeled oral cancer microenvironment mixtures, ST14-driven PAR2 activation predominates at low concentrations, whereas MMP1 and PRSS23 dominate at high concentrations, guiding antagonist design.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mmp1-and-prss23-induce-par2-biased-agonism-in-painful-oral-cancers/345854/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mmp1-and-prss23-induce-par2-biased-agonism-in-painful-oral-cancers/345854.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does PAR2 play in oral cancer pain?","Question",{"text":63,"@type":64},"PAR2 mediates oral cancer pain. It is activated by protease cleavage that unmasks an N-terminal tethered ligand.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do MMP1 and PRSS23 influence PAR2 signaling?",{"text":68,"@type":64},"MMP1 and PRSS23 drive protease-specific PAR2 redistribution (trafficking) and signaling patterns that differ from those produced by other proteases.",{"name":70,"@type":61,"acceptedAnswer":71},"Why do mixed-protease concentrations matter in this study?",{"text":72,"@type":64},"When proteases are mixed to model the oral cancer microenvironment, ST14-mediated PAR2 activation predominates at low protease concentrations, while MMP1 and PRSS23 prevail at high concentrations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345854,1790196673,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","communications biology Article  \nA Nature Portfolio journal  \n[https://doi.org/10.1038/s42003-026-10215-x](https://doi.org/10.1038/s42003-026-10215-x)  \nMMP1 and PRSS23 induce PAR2 biased agonism in painful oral cancers  \n Check for updates  \nPaulina D. Ramírez-García 1,2, Igor Dolgalev 3, Zinaida Dubeykovskaya1, Rocco Latorre2,4, Leticia Arbex1, Nguyen Huu Tu1,2, Brian L. Schmidt 1,2 & Donna G. Albertson 1,2   \nProtease-activated receptor 2 (PAR2) mediates oral cancer pain. Patients with metastatic (N +) cancers report greater pain. PAR2 is activated by N-terminal proteolytic cleavage. Here we show that proteases encoded by genes overexpressed in N+ cancers from patients with pain (matrix metallopeptidase 1, MMP1 and serine protease 23, PRSS23) elicit protease-speciﬁc receptor redistribution (trafﬁcking) and signaling that differs from that promoted by proteases encoded by genes not differentially expressed(transmembraneserine protease matriptase, ST14and cathepsinS, CTSS) . Mixtures of the proteases prepared to model the oral cancer microenvironment revealed that ST14-mediated PAR2 activation predominated at low protease concentrations. At high concentrations, MMP1 and PRSS23 prevailed over the greater potency of ST14 . We propose that PAR2 activation in oral N+ cancers from patients with pain is driven by high levels of MMP1 and PRSS23 . Our study informs design of signaling and location-speciﬁc antagonists to provide more efﬁcacious analgesia.  \nOral cancer patients experience pain atthe site of the cancer1–5. Pain is often the symptom that motivates oral cancer patients to seek treatment6,7. Seventy percent of patients self-report pain7, but the severity and nature of oral cancer pain varies among patients. Some patients report sensitivity to touch and interference with function. Others experience spontaneous pain and functional pain (i.e., pain when eating, talking and drinking), as well as sensitivity to touch and interference with function7. Patients with metastatic (N + ) cancers report experiencing greater pain than patients with nonmetastatic (N0) cancers7. Clinical experience supports the hypothesis that oral cancer pain originates in the tumor microenvironment(TME). Surgical resection of the cancer relieves pain5,7.  \nPAR2, encodedby F2RL1, a member ofthe familyofG-protein coupled receptors (GPCRs), mediates oral cancer pain8–15. PAR2 is activated by protease cleavage that unmasks an N-terminal tethered ligand16. Trypsin was identiﬁed as the ﬁrst PAR2-activating protease17. Trypsin and other proteases that cleave PAR2 at the same site (36R ↓ S37) lead to “canonical”PAR2 trafﬁcking and signaling. Proteasescan cleave PAR2 at different(noncanonical) sites and expose distinct tethered ligands that promote proteasespeciﬁc PAR2 trafﬁcking and signaling (biased agonism)16 and/or they can disarm PAR2 by removing the canonical cleavage site18.  \nThe oral cancer TME is enriched with dysregulated proteases that can both promote cancer19 and activate PAR27 at canonical and non-canonical sites. To date, one canonical protease, transmembrane serine protease 2 (TMPRSS2) and two non-canonical proteases, CTSS and legumain  \n(LGMN), have been reported to produce oral cancer pain via PAR29,20,21. None of these proteases, however, are overexpressed in N+ cancers from patients reporting high levels of pain. In addition, there are conﬂicting reports regarding whether TMPRSS2 is overexpressed or downregulated in oral cancer20,22. Thus, it is unclear to what extent PAR2-mediated oral cancer pain is driven by biased agonism.  \nTo better understand how PAR2 trafﬁcking and signaling might be altered in N+ oral cancers from patients reporting high pain compared to patients with N0 oral cancers7,23, we studied four proteases: two encoded by genes overexpressed in N+ oral cancers from patients reporting high levels of pain, MMP1 and PRSS237, together with ST14, a canonical protease with oncogenic roles in oral cancer24–27, and CTSS, a non-cano","cbCaipfaY4UcncKv","https://ap.wps.com/l/cbCaipfaY4UcncKv","pdf",3247522,14,"English","# Background\n## PAR2 activation and biased agonism\n## Tumor microenvironment proteases\n# Study Design\n## Protease selection and comparison\n## In vitro trafficking and signaling assays\n# Results\n## Concentration-dependent PAR2 activation\n## MMP1/PRSS23 versus ST14 and CTSS\n# Implications\n## Design of location-specific antagonists","[{\"question\":\"What role does PAR2 play in oral cancer pain?\",\"answer\":\"PAR2 mediates oral cancer pain. It is activated by protease cleavage that unmasks an N-terminal tethered ligand.\"},{\"question\":\"How do MMP1 and PRSS23 influence PAR2 signaling?\",\"answer\":\"MMP1 and PRSS23 drive protease-specific PAR2 redistribution (trafficking) and signaling patterns that differ from those produced by other proteases.\"},{\"question\":\"Why do mixed-protease concentrations matter in this study?\",\"answer\":\"When proteases are mixed to model the oral cancer microenvironment, ST14-mediated PAR2 activation predominates at low protease concentrations, while MMP1 and PRSS23 prevail at high concentrations.\"}]","MMP1 and PRSS23 induce PAR2 biased agonism in painful oral cancers | PDF",1790059130,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdfc0eed461caf155f5c1c366bafb394.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fd61852c58f8fd6e86de334e54d6238.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fbe08ebb9dd297a14ef4da341604082.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/263e6e456f43735dfe65e33378bbab7d.webp",980,1301]